A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 4, Pages e1303584
Publisher
Informa UK Limited
Online
2017-04-11
DOI
10.1080/2162402x.2017.1303584
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?
- (2018) David Bruce et al. CELL COMMUNICATION AND ADHESION
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current progress in immunotherapy for pancreatic cancer
- (2016) Kelly Foley et al. CANCER LETTERS
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
- (2016) Paul R. Kunk et al. Journal for ImmunoTherapy of Cancer
- Pancreatic Ductal Adenocarcinoma
- (2016) Megan B. Wachsmann et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
- (2015) Hiroki Yamaue et al. CANCER SCIENCE
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
- (2015) Ignacio Garrido-Laguna et al. Nature Reviews Clinical Oncology
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Pathological and Molecular Evaluation of Pancreatic Neoplasms
- (2015) Arvind Rishi et al. SEMINARS IN ONCOLOGY
- Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial
- (2015) Friedrich H Schmitz-Winnenthal et al. OncoImmunology
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Vaccine therapy for pancreatic cancer
- (2014) Bulent Salman et al. OncoImmunology
- Pancreatic cancer
- (2014) Daniel Abate-Daga et al. OncoImmunology
- Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
- (2013) Felix Klug et al. CANCER CELL
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer
- (2013) Seung Ho Kim et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
- (2013) W. Joost Lesterhuis et al. PLoS One
- Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors
- (2013) F. Sandoval et al. Science Translational Medicine
- Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy
- (2012) Z.-C. Ding et al. BLOOD
- Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer
- (2012) Andreas G Niethammer et al. BMC CANCER
- Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors
- (2012) Isamu Okamoto et al. CANCER SCIENCE
- Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases
- (2012) M. Shibuya JOURNAL OF BIOCHEMISTRY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2
- (2011) Jennifer Spratlin Current Oncology Reports
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- Biopsy Targeting Gliomas
- (2010) Marc-André Weber et al. INVESTIGATIVE RADIOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts
- (2009) C. Jandus et al. CANCER RESEARCH
- Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
- (2009) Motoki Miyazawa et al. CANCER SCIENCE
- VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
- (2009) Hiroyuki Suzuki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma
- (2009) Andreas Bonertz et al. JOURNAL OF CLINICAL INVESTIGATION
- Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis
- (2008) Rong Xiang et al. IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation